At the crossroads of targeted treatment and resistance in melanoma

Lancet Oncol. 2013 Apr;14(4):e136-7. doi: 10.1016/S1470-2045(13)70108-6.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Humans
  • Melanoma / drug therapy*
  • Mutation*
  • Proto-Oncogene Proteins B-raf / antagonists & inhibitors*
  • Proto-Oncogene Proteins B-raf / genetics*

Substances

  • Proto-Oncogene Proteins B-raf